



Aastrom Biosciences to Present At Merriman Curhan Ford & Co. 4th Annual Investor Summit

ANN ARBOR, Mich., Sep 13, 2007 (PrimeNewswire via COMTEX News Network) --

Aastrom Biosciences, Inc. (Nasdaq:ASTM) today announced that Sheldon A. Schaffer, Ph.D., Vice President, Corporate Development & Intellectual Property, will present at the Merriman Curhan Ford & Co. 4th Annual Investor Summit. The conference will be held September 17-18th at The Mark Hopkins InterContinental Hotel in San Francisco, CA. Aastrom will present on Monday, September 17th at 1:15 p.m. (Pacific Time) or 4:15 p.m. (Eastern Time).

A live webcast of Aastrom's presentation can be accessed by logging onto the web at <http://wsw.com/webcast/mcm7/astm/>. A replay of the presentation will be archived for 90 days at the same site. For more information about the Merriman Curhan Ford & Co. conference, please visit <http://www.merrimanco.com/>.

About Aastrom Biosciences, Inc.

Aastrom is a regenerative medicine company developing autologous cell products for the repair or regeneration of bone, vascular, cardiac and neural tissues, based on its proprietary Tissue Repair Cell (TRC) Technology. Aastrom's TRC-based products contain a unique cell mixture of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. TRC-based products have been used in over 250 patients to date and are being clinically evaluated for bone regeneration to treat osteonecrosis of the femoral head (U.S.: ON-CORE Phase III trial and Spain: pivotal trial), and vascular regeneration in patients with critical limb ischemia (U.S.: RESTORE-CLI Phase IIb trial and Germany: Phase I/II trial). Aastrom has recently completed a U.S. Phase I/II severe non-union fracture clinical trial, and is also developing programs to address cardiac and neural regeneration indications. TRC-based products have received Orphan Drug Designation from the FDA for use in the treatment of osteonecrosis of the femoral head and the treatment of dilated cardiomyopathy, a severe chronic heart disease.

For more information, visit Aastrom's website at www.aastrom.com. (astmc)

The Aastrom Biosciences, Inc. logo is available at <http://www.primenewswire.com/newsroom/prs/?pkgid=3663>

This document contains forward-looking statements, including without limitation, statements concerning planned clinical trials and activities and anticipated timing of clinical events, product development objectives, and potential product applications, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "expected," "anticipated," "planned," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are potential patient accrual difficulties, clinical trial results, potential product development difficulties, the effects of competitive therapies, regulatory approval requirements, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc.

Investor Relations Department
Kris M. Maly
(734) 930-5777

Cameron Associates
Kevin McGrath
(212) 245-4577

Media
Deanne Eagle
(212) 554-5463

News Provided by COMTEX